Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: CNS Drugs. 2011 Jul 1;25(7):555–573. doi: 10.2165/11587830-000000000-00000

Figure 5. Human IgMs promote neural growth.

Figure 5

A. A single dose of 500 μg of rHIgM22 promotes remyelination of the demyelinated lesions in the TMEV MS model. A1. rHIgM22 binds to primary rat oligodendrocyte. A2. Demyelinated lesions as seen in the control IgM-treated mice. A3. Enhanced remyelination was observed following rHIgM22 treatment. A4. Quantitation of remyelination following treatment with control IgM versus rHIgM22 (p<0.05, unpaired t-test). B. rHIgM12 bound to neuronal surface (B1). E15 hippocampal neurons from FVB mice were grown on nitrocellulose-attached glass coverslips coated with PDL (B2) or rHIgM12 (B3) substrates. Neurite length was measured 12 hr after plating of cells. Total neurite length was quantified and neurons grown on rHIgM12 substrate showed increased neurite length compared to the control (B4) (p<0.05, unpaired t-test). PDL was used as the control substrate because the non-specific IgMs did not support neuron attachment.